News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bradley Pharmaceuticals (BDY) to Report Second Quarter 2007 Financial Results and Schedules Conference Call


7/31/2007 10:44:04 AM

FAIRFIELD, N.J., July 31 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. announced today that the Company will release its second quarter 2007 financial results on Thursday, August 9, 2007, after the close of the financial markets. Daniel Glassman, President and CEO, will host a conference call on Friday, August 10, 2007 at 8:30 a.m. Eastern Time to review the results for the quarter.

To participate in the call via telephone, please dial 1-888-573-3046 approximately 10 minutes prior to the start of the call and enter ID #11333497. A conference call replay will be available after 1:00 PM ET by calling 1-800-642-1687 and entering reservation ID #11333497.

To access the call live on the Internet, please visit the Investor Relations section on the Company's website at www.bradpharm.com. The call will be available on the web page for 30 days.

For more information about Bradley Pharmaceuticals, please visit: www.bradpharm.com.

About Bradley Pharmaceuticals, Inc.

Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that, upon approval, leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Safe Harbor for Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. Actual results may differ materially from those projected. These risks and uncertainties include those described from time to time in Bradley's SEC filings, including its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Except as required by law, Bradley undertakes no obligation to publicly update any forward-looking statement in this press release, whether as a result of new information, future events or otherwise.

Bradley Pharmaceuticals, Inc.

CONTACT: Cecelia C. Heer, Investor and Public Relations, of BradleyPharmaceuticals, Inc., +1-973-882-1505, ext. 252, or cheer@bradpharm.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES